Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy

• Published in: Clinical infectious diseases Vol. 50; no. 10; pp. 1419 - 1421
• Main Authors: Evans-Jones, John G., Cottle, Lucy E., Back, David J., Gibbons, Sara, Beeching, Nicholas J., Carey, Peter B., Khoo, Saye H.
• Format: Journal Article
• Language: English
• Published: Oxford The University of Chicago Press 15.05.2010; University of Chicago Press; Oxford University Press
• Subjects: Adult; Aged; Anti-HIV Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretroviral drugs; Antiretroviral Therapy, Highly Active; Antiretrovirals; Antiviral agents; Antivirals; Biological and medical sciences; Clinical medicine; Dosage; Drug Interactions; Drug therapy; Ethnicity; Female; Health Services Research; HIV; HIV Infections - drug therapy; HIV/AIDS; Human immunodeficiency virus; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Male; Medical sciences; Medications; Middle Aged; Patients; Pharmacology. Drug treatments; Physicians; Prescription drugs; Proteases; Risk Assessment; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral load; Young Adult; Infection; Immunopathology; Antiretroviral agent; Chemotherapy; Treatment; Viral disease; Risk factor; Antiviral; AIDS; Drug interaction; Immune deficiency
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1086/652149

We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.